<DOC>
<DOCNO>
EP-0016274
</DOCNO>
<TEXT>
<DATE>
19801001
</DATE>
<IPC-CLASSIFICATIONS>
C07D-457/00 A61P-25/02 C07D-221/00 C07D-457/06 C07D-471/00 A61P-25/16 A61P-25/00 A61P-25/20 C07D-457/02 A61K-31/48 A61K-31/47 <main>C07D-471/06</main> C07D-471/06 C07D-221/10 
</IPC-CLASSIFICATIONS>
<TITLE>
2-azaergolines and 2-aza-8(or 9)-ergolenes, process for their preparation and pharmaceutical compositions containing them.
</TITLE>
<APPLICANT>
lilly co eli us<sep>eli lilly and company<sep>eli lilly and company307, east mccarty streetindianapolis indiana 46285us<sep>eli lilly and company<sep>
</APPLICANT>
<INVENTOR>
bach nicholas james<sep>kornfeld edmund carl<sep>bach, nicholas james<sep>kornfeld, edmund carl<sep>bach, nicholas james4269 burkhard street, e. driveindianapolis indianaus<sep>kornfeld, edmund carl5159, east 76th courtindianapolis indianaus<sep>bach, nicholas james<sep>kornfeld, edmund carl<sep>bach, nicholas james4269 burkhard street, e. driveindianapolis indianaus<sep>kornfeld, edmund carl5159, east 76th courtindianapolis indianaus<sep>
</INVENTOR>
<ABSTRACT>
novel 2-azaergolines, 2-aza-8(or 9)-ergolenes, which are  neuroleptic agents, are described herein.  these compounds  are prepared by reacting a 7-amino-6-ketobenzo[f]quinoline  with a diazotization agent.  e. g.  sodium nitrite and a strong  mineral acid, to yield the 6-keto-7-diazonium salt intermediÂ­ ate, followed by reduction to yield the final product.  
</ABSTRACT>
</TEXT>
</DOC>
